IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Revenue for the Biological and Biochemical Product Manufacturing industry has increased at a CAGR of 16.7% to $96.7 billion over the past five years, including a growth rate of 6.1% in 2024 alone, when profit will be 11.5%. The industry has benefited from the development of the national economy, rising household disposable incomes and increasing investment in the healthcare sector by the government. Improvements in China's social security system, the establishment of a public health system and the formation of the new rural cooperative medical care system have boosted demand for industry products, particularly vaccines. Under the influence of the COVID-19 pandemic, people's willingness to receive flu vaccines and other types of vaccines has also been greatly increased.China has many industry companies compared with the international market, but these companies are usually small in scale. The industry therefore has a low concentration level, with the top four players accounting for 14.8% of total revenue in the current year. The industry's range of industry products is wide and growing, and most companies only manufacture one type of product or several related products, which keeps market share concentration low. Foreign investment in the industry has been increasing over the past five years, as industry conditions are favorable and it has future growth potential. This factor has boosted competition over the period, and many enterprises have enlarged their scale, diversified their product ranges and worked to establish internationally renowned brands. Industry revenue is forecast to grow at a CAGR of 7.2% over the five years through 2029, to total $136.9 billion.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Biological and Biochemical Product Manufacturing industry in China includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released July 2025.
The Biological and Biochemical Product Manufacturing industry in China operates under the industry code 2760. Industry operators manufacture biological and biochemical products and genetically engineered drugs like vaccines, blood products, and diagnostic reagents. Related terms covered in the Biological and Biochemical Product Manufacturing industry in China include over the counter (otc), good manufacturing practice (gmp), good selling practice (gsp), new cooperative medical care system and health centers.
Products and services covered in Biological and Biochemical Product Manufacturing industry in China include Genetically engineered products , Blood products and Diagnostic reagents.
Companies covered in the Biological and Biochemical Product Manufacturing industry in China include Chongqing Zhifei Biological Products Co., Ltd., Changchun High-Tech Industry (Group) Inc. and China National Biotec Group Company Limited.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Biological and Biochemical Product Manufacturing industry in China.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Biological and Biochemical Product Manufacturing industry in China.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Biological and Biochemical Product Manufacturing industry in China.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Biological and Biochemical Product Manufacturing industry in China. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Biological and Biochemical Product Manufacturing industry in China. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Biological and Biochemical Product Manufacturing industry in China. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Biological and Biochemical Product Manufacturing industry in China. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Biological and Biochemical Product Manufacturing industry in China.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Biological and Biochemical Product Manufacturing industry in China is $96.7bn in 2026.
There are 1,380 businesses in the Biological and Biochemical Product Manufacturing industry in China, which has grown at a CAGR of 8.6 % between 2020 and 2025.
The Biological and Biochemical Product Manufacturing industry in China is likely to be impacted by import tariffs with imports accounting for a moderate share of industry revenue.
The Biological and Biochemical Product Manufacturing industry in China is likely to be impacted by export tariffs with exports accounting for a moderate share of industry revenue.
The market size of the Biological and Biochemical Product Manufacturing industry in China has been growing at a CAGR of 16.7 % between 2020 and 2025.
Over the next five years, the Biological and Biochemical Product Manufacturing industry in China is expected to grow.
The biggest companies operating in the Biological and Biochemical Product Manufacturing industry in China are Chongqing Zhifei Biological Products Co., Ltd., Changchun High-Tech Industry (Group) Inc. and China National Biotec Group Company Limited
Genetically engineered products and Blood products are part of the Biological and Biochemical Product Manufacturing industry in China.
The company holding the most market share in the Biological and Biochemical Product Manufacturing industry in China is Chongqing Zhifei Biological Products Co., Ltd..
The level of competition is moderate and increasing in the Biological and Biochemical Product Manufacturing industry in China.